June 21, 2021 07:14 AM EDT
R&D

No­var­tis bur­nish­es Zol­gens­ma da­ta in presymp­to­matic pa­tients as Roche's Evrys­di con­tin­ues eat­ing away at the SMA pie

Max Gelman

Senior Editor

With sales slow­ing and Roche’s Evrys­di hot on its tail, No­var­tis’ Zol­gens­ma for spinal mus­cu­lar at­ro­phy is seek­ing to build a sta­ble of da­ta in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times